Multiple RSV vaccines in late-stage development show promise in older adults

WASHINGTON — Three late-breaking studies offered a promising glimpse of respiratory syncytial virus vaccines in the pipeline for older adults — including the RSVPreF3 OA vaccine, which showed an overall vaccine efficacy of about 83%.

Related Keywords

United States ,Washington ,Jordan ,Edwarde Walsh ,Byjohnc Schoen ,Roberth Hopkins Jr ,Caroll Diberardino , ,Pfizer ,University Of Rochester ,Northwestern Medicine ,Elke Jordan ,